Karrie Ka Wai Wong

TRACE identifies tumor-reactive CD8+ T cells across solid tumors using clonotype-level classification and scRNA-seq data, showing high accuracy and specificity for tumor-experienced T cells.

This study identifies Regnase-1 and SOCS1 dual-inactivation as a strategy to enhance anti-tumor functionality of CD8+ T cells by rewiring their differentiation and effector state.

This study uses CRISPR/Cas9 screens to identify SOCS1 as a target for enhancing T cell therapy, leading to the development of an engineered TIL therapy with improved anti-tumor function.